| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2021-05-13 | Biogen (USA - MA) Envisagenics (USA - NY) | artificial intelligence (AI)-driven RNA splicing platform, SpliceCore® | CNS diseases |
collaboration
research
|
CNS diseases - Neurological diseases - Neurodegenerative diseases | Research agreement |
| 2021-05-12 | Biogen (USA - MA) TMS Co (Japan) | TMS-007, an investigational drug for acute ischemic stroke | acute ischemic stroke | product acquisition | Cerebrovascular diseases - Cardiovascular diseases | Product acquisition |
| 2021-02-11 | Ensoma (USA - MA) Takeda (Japan) | five undisclosed rare diseases | licensing | Rare diseases | Licensing agreement | |
| 2021-01-18 | ViGeneron (DE) Daiichi-Sankyo (Japan) | engineered adeno-associated virus (vgAAV) | undisclosed | research | Ophthalmological diseases | Research agreement |
| 2021-01-05 | Biogen (USA - MA) ViGeneron (DE) | gene therapy products based on adeno-associated virus (AAV) vectors | inherited eye diseases | collaboration licensing | Ophthalmological diseases | Licensing agreement |
| 2020-12-01 | ViGeneron (DE) WuXi Advanced Therapies (USA - PA) | VG901 | retinitis pigmentosa | development manufacturing | Ophthalmological diseases | Production agreement |
| 2020-03-23 | Soligenix (USA - NY) the University of Hawaii (USA) | COVID-19, coronavirus infection | research | Infectious diseases | Research agreement | |
| 2020-02-26 | Gemini Therapeutics (USA) - Singapore Eye Research Institute (SG) | new targets associated with age-related macular degeneration | Age-related Macular Degeneration (AMD), polypoidal choroidal vasculopathy | R&D | Ophthalmological diseases - Cardiovascular diseases | Research agreement |
| 2020-02-12 | Sangamo Therapeutics (USA - CA) | member of the board | nomination | Nomination | ||
| 2019-12-23 | Sangamo Therapeutics (USA - CA) Pfizer (USA - NY) | gene therapy programs for hemophilia A, including SB-525 | hemophilia A | licensing - development - commercialisation | Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2019-11-26 | Sangamo Therapeutics (USA - CA) | member of the board | nomination | Nomination | ||
| 2019-11-08 | Sangamo Therapeutics (USA - CA) | scientific advisory board | nomination | Nomination | ||
| 2019-09-30 | Sangamo Therapeutics (USA - CA) | senior vice president, chief medical officer | nomination | Nomination | ||
| 2019-09-13 | Gemini Therapeutics (USA) | CEO | nomination | Rare diseases - Genetic diseases- Ophthalmological diseases | Nomination | |
| 2019-07-31 | Sangamo Therapeutics (USA - CA) | executive vice president and general counsel | nomination | Nomination | ||
| 2019-06-19 | Genzyme (USA - MA), a Sanofi company (France) Voyager Therapeutics (USA - MA) | gene therapy programs for Parkinson’s disease, Friedreich’s ataxia, Huntington’s disease and other CNS disorders | Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease and other CNS disorders | development - commercialisation | CNS diseases - Neurodegenerative diseases | Development agreement |
| 2019-05-20 | Voyager Therapeutics (USA-MA) | head of R&D | nomination | Neurological diseases - Neurodegenerative diseases | Nomination | |
| 2019-04-02 | Sangamo Therapeutics (USA - CA) Brammer Bio (USA - CA) | large-scale AAV manufacturing | manufacturing - production | Production agreement | ||
| 2019-03-12 | Sangamo Therapeutics (USA - CA) | senior vice president cell therapy | nomination | Nomination | ||
| 2019-02-27 | Sangamo Therapeutics (USA - CA) Biogen (USA - MA) | ST-501, ST-502, and a neuromuscular target | tauopathies including Alzheimer’s disease, synucleinopathies including Parkinson’s disease | licensing - development - commercialisation | Neurological diseases - Neurodegenerative diseases - Neuromuscular diseases | Licensing agreement |
